Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06555133 · ClinicalTrials.gov registry record · Phase 2
Y-90, Capecitabine, and Atezolizumab for Oligometastatic CRC
A Phase 2 study of Colorectal Carcinoma Metastatic in the Liver, sponsored by Brown University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT06555133 is a Phase 2 study of Colorectal Carcinoma Metastatic in the Liver that is actively recruiting participants, run by Brown University. The registered enrollment target is 18 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06555133, a Phase 2 study of Colorectal Carcinoma Metastatic in the Liver, is actively recruiting participants, sponsored by Brown University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
BrUOG-430 is a prospective, single-arm, phase 2 trial evaluating yttrium-90 radioembolization in combination with capecitabine and atezolizumab for the treatment of unresectable colorectal cancer liver metastases in individuals who have been treated with two or more lines of systemic therapy.
Conditions Studied
Interventions
- COMBINATION_PRODUCT yttrium-90 radioembolization
Study Locations (1)
Rhode Island
- Lifespan Cancer Institute: The Miriam and Rhode Island Hospitals Providence, Rhode Island, United States, 02903 Contact: - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2025-04-07 |
| Est. Completion | 2029-09-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06555133
The ClinicalTrials.gov registry entry for NCT06555133 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brown University, which has 231 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Colorectal Carcinoma Metastatic in the Liver appearing as the primary indexed condition, and to 1 intervention - of which yttrium-90 radioembolization is the first listed.
NCT06555133 reports 1 study location spanning 1 distinct geographic area - top geographies include Rhode Island.
Frequently Asked Questions
What is clinical trial NCT06555133 about?
NCT06555133 is a clinical study titled "Y-90, Capecitabine, and Atezolizumab for Oligometastatic CRC". BrUOG-430 is a prospective, single-arm, phase 2 trial evaluating yttrium-90 radioembolization in combination with capecitabine and atezolizumab for the treatment of unresectable colorectal cancer liver metastases in individuals who have been treated with two or more lines of systemic therapy.
What is the current status of trial NCT06555133?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2025-04-07. Estimated completion is 2029-09-01.
What conditions does trial NCT06555133 study?
This clinical trial studies the following conditions: Colorectal Carcinoma Metastatic in the Liver.
What interventions are being tested in trial NCT06555133?
The interventions under investigation include: yttrium-90 radioembolization (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06555133?
This trial is sponsored by Brown University, which has 231 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06555133 being conducted?
This trial has 1 study location across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Carcinoma Metastatic in the Liver
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer
ACTIVE NOT RECRUITING · Phase 1
-
An Imaging Agent (I-124 M5A) in Detecting CEA-Positive Liver Metastases in Patients With Colorectal Cancer
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.